Clinical trials: Intraocular Inflammation
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Non-infectious Anterior Uveitis
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
- Trial name
- NCT03131154
- Testing
- ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
- Where
- 27 sites in United States
- Volunteers
- 123 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Non-infectious Intermediate Posterior- or Pan-uveitis
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life.
- Trial name
- NCT05414201
- Testing
- Adalimumab
- Where
- 7 sites in China
- Volunteers
- 87 people
- Sponsor
- AbbVie
Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
Study of FTY720 in Patients With Uveitis
This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis
- Trial name
- NCT01791192
- Testing
- FTY720, Oral Corticosteroid
- Sponsor
- Novartis Pharmaceuticals
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Behçet Disease
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups.
- Trial name
- NCT04609397
- Testing
- Hemay005
- Where
- 31 sites in China
- Volunteers
- 89 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Uveitis
Flare Photometry in Uveitis Patients
This is a cross sectional study of a novel non-invasive optical flare photometer (OFAM). Patients meeting the inclusion/exclusion criteria will receive a standard eye examination including a slit lamp examination to collect…
- Trial name
- NCT01897935
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ChromoLogic, LLC
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Uveitis, Posterior
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.
- Trial name
- NCT05322070
- Testing
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Alimera Sciences
Uveitis
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
- Trial name
- EYEGUARD™-E (NCT02258854)
- Testing
- Dose 2 gevokizumab
- Where
- 33 sites in United States
- Volunteers
- 69 people
- Sponsor
- XOMA (US) LLC
Non-infectious Uveitis
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown…
- Trial name
- NCT03634475
- Testing
- PP-001
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Panoptes Pharma GmbH
Behcet Disease
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.
- Trial name
- Behcet (NCT02756650)
- Testing
- Canakinumab
- Where
- Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Active Non-anterior, Non-infectious Uveitis
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
- Trial name
- NCT07552012
- Testing
- FXS5626 tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Uveitis
Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
- Trial name
- NCT05180526
- Testing
- QLETLI
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions
Uveitis
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.
- Trial name
- VISUAL III (NCT01148225)
- Testing
- adalimumab
- Volunteers
- 424 people
- Sponsor
- AbbVie
Axial Spondylarthritis (axSpA)
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior…
- Trial name
- UP-FOR-U (NCT07018206)
- Testing
- Upadacitinib 15 MG [Rinvoq]
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- CARE ARTHRITIS LTD.
Inflammation, Cataract
Study of Dexycu in Treating Intraocular Inflammation
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of…
- Trial name
- NCT06429306
- Testing
- Dexycu
- Where
- China
- Volunteers
- 285 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06723106
- Testing
- RAY121
- Where
- 62 sites in Australia, Austria and 17 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Anterior Uveitis
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of uveitis.
- Trial name
- NCT00405496
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 24 people
- Sponsor
- Sirion Therapeutics, Inc.
Active Noninfectious Uveitis Affecting the Posterior Segment
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.
- Trial name
- TITAN (NCT07218770)
- Testing
- REGN7041
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Regeneron Pharmaceuticals